NUGC-3 Xenograft Model Service for Gastric Cancer

The NUGC-3 xenograft model offers a robust, well-characterized preclinical platform for evaluating therapeutic efficacy against gastric adenocarcinoma in vivo. At Alfa Cytology, we specialize in building validated, GLP-compliant NUGC-3 xenograft systems tailored to your discovery pipeline---from pilot pharmacology studies to large-scale combination therapy assessments---ensuring reproducible tumor kinetics and clinically translatable endpoints.

Overview of NUGC-3 Xenograft Model for Gastric Cancer

The NUGC-3 cell line was established from a poorly differentiated gastric adenocarcinoma and has been extensively utilized as a cell-derived xenograft (CDX) model in preclinical oncology research. When implanted into immunocompromised murine hosts, NUGC-3 cells recapitulate key histopathological features of human gastric cancer, including glandular disorganization, high mitotic activity, and aberrant expression of oncogenic signaling molecules such as EGFR, HER2, and VEGF. The model supports both subcutaneous and orthotopic implantation routes, enabling flexible study designs that range from primary tumor growth inhibition to metastasis and peritoneal dissemination assays.

NUGC-3 xenografts exhibit a relatively rapid tumor take rate and consistent growth kinetics, making them particularly suitable for high-throughput drug screening and biomarker validation. The model has been employed to evaluate cytotoxic agents, targeted small molecules, antibody-drug conjugates, and combination regimens, providing pharmacologically relevant data on tumor regression, time-to-progression, and survival benefit. Additionally, luciferase-engineered NUGC-3 derivatives enable longitudinal, non-invasive monitoring via bioluminescence imaging, further enhancing the translational value of this platform for gastric cancer drug development.

Figure 1. NCA inhibits the growth of HGC-27 and NUGC-3 cells. (Sun, Wenqiang, et al., 2025)

Cell Line Information: NUGC-3

NUGC-3 (Nagoya University-Gastric Cancer-3) is a human gastric adenocarcinoma cell line originally isolated from a 72-year-old male patient of Japanese ethnicity. The line was established at Nagoya University and has been authenticated and distributed by the Japanese Collection of Research Bioresources (JCRB; JCRB0822). It exhibits anchorage-dependent growth in vitro and demonstrates robust tumorigenicity in immunodeficient mice, forming xenografts that maintain the poorly differentiated histology of the primary tumor. The following table summarizes the essential characteristics of the NUGC-3 cell line.

Our Services

Alfa Cytology delivers end-to-end NUGC-3 xenograft services engineered for reproducibility and regulatory readiness. Our platform integrates stringent cell-line authentication, standardized inoculation protocols, and comprehensive endpoint analytics---tumor volume caliper measurements, bioluminescence imaging, histopathology, and pharmacokinetic/pharmacodynamic correlation---to accelerate your gastric cancer program from lead optimization to IND-enabling studies.

Workflow of NUGC-3 Xenograft Model Construction

Alfa Cytology follows a standardized, quality-controlled workflow to establish NUGC-3 xenografts, ensuring batch-to-batch consistency and high tumor engraftment rates. Each project is initiated with a feasibility consultation to define the route of implantation, dosing schedule, and endpoint criteria aligned with the therapeutic mechanism under investigation.

1. Step 1: Cell Line Authentication & Expansion: NUGC-3 cells are revived from authenticated master stocks (JCRB0822) and expanded under GMP-aligned culture conditions. Mycoplasma, sterility, and STR identity confirmation are performed prior to inoculation to guarantee genetic fidelity.
2. Step 2: Host Selection & Acclimatization: Immunocompromised mice (nude or NSG strains, 6-8 weeks old) are acclimatized for at least 5 days. Health status is verified by body-weight monitoring and veterinary inspection before tumor cell inoculation.
3. Step 3: Tumor Cell Inoculation: NUGC-3 cells are harvested at logarithmic growth phase, washed, and resuspended in a 1:1 mixture of serum-free medium and Matrigel (or PBS for orthotopic models). Subcutaneous flank injections (1x10^6-5x10^6 cells) or orthotopic gastric wall injections are performed under aseptic conditions.
4. Step 4: Tumor Establishment Monitoring: Animals are monitored daily for body weight and general condition. Subcutaneous tumors are measured by digital caliper twice weekly; orthotopic tumors are tracked via bioluminescence imaging (for luciferase-labeled NUGC-3) or micro-ultrasound. Tumor volumes are calculated using the modified ellipsoid formula (L x W^2 / 2).
5. Step 5: Randomization & Treatment Initiation: Once tumors reach 100-200 mm^3, animals are randomized into treatment and vehicle-control cohorts based on tumor volume and body weight. Dosing regimens are initiated according to the study protocol, with dosing volumes and frequencies optimized for the compound class.
6. Step 6: In-Life Endpoint Assessment: Throughout the study, clinical signs, body weight, and tumor dimensions are recorded. Blood samples may be collected for pharmacokinetic analysis. Tumor growth inhibition (TGI), partial and complete response rates, and time-to-doubling are calculated in real time.
7. Step 7: Necropsy & Histopathological Analysis: At study termination, tumors and relevant organs are excised, weighed, and fixed in 10% neutral buffered formalin. Hematoxylin and eosin (H&E) staining, immunohistochemistry (IHC) for Ki-67, cleaved caspase-3, and target-specific markers, and TUNEL assays are performed to characterize treatment effects.
8. Step 8: Data Compilation & Reporting: All raw data, statistical analyses, and histological images are compiled into a comprehensive study report. Data packages include tumor growth curves, waterfall plots, survival Kaplan-Meier curves, and pharmacodynamic summaries suitable for regulatory submission or publication.

Figure 2: Schematic workflow illustrating the derivation and construction of the NUGC-3 Xenograft Model at Alfa Cytology.

Case Study-NUGC-3 Xenograft Model Development

In a representative engagement, Alfa Cytology established subcutaneous NUGC-3 xenografts in female NSG mice to evaluate a novel HER2-targeted antibody-drug conjugate. Following successful engraftment with a tumor take rate exceeding 90%, animals were randomized and dosed according to a multi-arm schedule. The study captured dose-dependent tumor growth inhibition, with the highest dose cohort demonstrating sustained regression over a 28-day treatment window. Pharmacodynamic profiling of excised tumors revealed downregulation of proliferation markers and induction of apoptosis, supporting the mechanism of action hypothesized by the sponsor. Full histopathological and biomarker datasets were delivered in a regulatory-compliant report, enabling the client to advance the candidate into GLP toxicology studies.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor with operational flexibility to deliver NUGC-3 xenograft data that withstands regulatory scrutiny and accelerates pipeline decisions. Our dedicated oncology team ensures every study is designed with translational relevance in mind.

• Validated, authenticated NUGC-3 master cell banks with documented STR profiles and mycoplasma-free certification.
• Flexible implantation routes (subcutaneous, orthotopic, peritoneal dissemination) to match your mechanistic and therapeutic hypotheses.
• Integrated bioluminescence and micro-ultrasound imaging capabilities for real-time, non-invasive tumor monitoring.
• Customizable dosing schedules and combination arms, including chemotherapy, targeted therapy, and immunotherapy co-administrations.
• Comprehensive endpoint analytics encompassing tumor growth kinetics, survival analysis, histopathology, and biomarker quantification.
• Regulatory-compliant data packages and GLP-ready study reports to support IND filings and peer-reviewed publications.

Contact Us

Ready to advance your gastric cancer therapeutic program with a validated NUGC-3 xenograft model? Please reach out to us today via our inquiry form or email to learn more about our NUGC-3 Xenograft Model services.

For research use only. Not intended for any clinical use.